Medtronic reports third quarter fiscal 2024 financial results

Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance

Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024 .

Key Highlights

  • Revenue of $8.1 billion increased 4.7% as reported and 4.6% organic

  • GAAP diluted earnings per share (EPS) of $0.99 ; non-GAAP diluted EPS of $1.30

  • Raises FY24 organic revenue growth and EPS guidance

  • Company provides portfolio management update on Patient Monitoring and Respiratory Interventions businesses

  • Received U.S. FDA approval for PulseSelect™ pulsed field ablation (PFA) system and Percept™ RC neurostimulator with BrainSense™ technology; CE Mark for MiniMed™ 780G System with Simplera Sync™ CGM and Micra™ AV2 and Micra™ VR2 leadless pacemakers

Financial Results
Medtronic reported Q3 worldwide revenue of $8.089 billion , an increase of 4.7% as reported and 4.6% on an organic basis. The company's organic revenue results reflect continued momentum across the company, driven by strong growth in Diabetes, Core Spine, Cardiac Surgery, Structural Heart, and Cardiac Pacing, as well as strength in international markets. The organic revenue growth comparison excludes:

  • Revenue of $17 million and the associated $2 million unfavorable impact from foreign currency translation reported as Other, stemming from business separations; and

  • The favorable impact from foreign currency translation of $70 million on the remaining segments.

As reported, Q3 GAAP net income and diluted EPS were $1.322 billion and $0.99 , respectively, both representing increases of 8%. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income of $1.728 billion and non-GAAP diluted EPS of $1.30 were both flat. Included in non-GAAP diluted EPS was an 11 cent , or 8%, unfavorable impact from foreign currency translation.

"We're building momentum, with another quarter of solid execution on our commitments. We continue to deliver durable revenue growth, with particular strength in multiple businesses, as well as in international markets as we expand access to our innovative healthcare technologies around the globe," said Geoff Martha , Medtronic chairman and chief executive officer. "Our recent major product approvals – including transformative products in the diabetes, cardiac rhythm management, neuromodulation, hypertension, and pulsed field ablation spaces – increase our confidence in driving reliable growth over the coming quarters and years."

Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $2.929 billion increased 6.1% as reported and 5.1% organic, with a low-double digit organic increase in SHA, mid-single digit organic increases in CPV, and low-single digit increase in CRHF.

  • CRHF results included low-single digit growth in Cardiac Rhythm Management, driven by high-single digit growth in Cardiac Pacing Therapies, including mid-teens growth in Micra™ transcatheter pacing systems; Cardiac Ablation Solutions grew low-double digits in international markets

  • SHA driven by low-double digit growth in both Aortic and Cardiac Surgery; Structural Heart grew high-single digits, with double digit growth in Western Europe and Japan on the adoption of Evolut™ FX

  • CPV delivered high-single digit growth in Coronary on growth in guide catheters, balloons, and drug-eluting stents; Peripheral Vascular Health grew mid-single digits, with low-double digit growth in Vascular Embolization products, high-single digit growth in drug-coated balloons

  • Received U.S. FDA approval and CE Mark for PulseSelect™ pulsed field ablation (PFA) system, with first commercial cases occurring in fiscal Q4, and the Nitron CryoConsole™ system; Received CE Mark for Micra™ AV2 and Micra™ VR2 next generation leadless pacemakers

Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.355 billion increased 4.8% as reported and 4.3% organic, with a mid-single digit organic increase in CST, low-single digit organic increases in Specialty Therapies and flat organic results in Neuromodulation.

  • CST overall performance was driven by continued adoption of the company's AiBLE™ ecosystem, with high-single digit global and U.S. growth in Core Spine, mid-teens global and U.S. growth in Biologics, and mid-single digit growth in Neurosurgery

  • Specialty Therapies results driven by mid-single digit growth in Neurovascular, including double digit growth in flow diversion; ENT grew mid-single digits with strength in power capital and disposables and localized drug delivery sinus implants; Pelvic Health results driven by mid-single digit growth in sacral neuromodulation on the continued adoption of the InterStim X™ system, offset by a product line divestiture

  • Neuromodulation results included low-single digit growth in Brain Modulation, with mid-teens Western Europe growth on launch of the Percept™ RC neurostimulator with BrainSense™ technology; Pain Stim results were flat, with low-single digit growth in the U.S.

Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Patient Monitoring & Respiratory Interventions (PMRI) divisions. Revenue of $2.148 billion increased 3.9% as reported and 2.9% organic, with low-single digit organic increases in both SE and PMRI. Excluding sales of ventilators, which declined mid-twenties, both Medical Surgical and PMRI grew mid-single digits organic.

  • SE results included mid-single digit growth in General Surgical Technologies, with strength in wound management and hernia products, low-single digit growth in Advanced Surgical Technologies, and mid-single growth in Endoscopy

  • PMRI results driven by mid-single digit growth in Patient Monitoring, with high twenties growth in Nellcor™ pulse oximetry monitors; Respiratory Interventions results declined mid-single digit, with low-single digit growth in Airways offset by declines in ventilator sales

Diabetes
Diabetes revenue of $640 million increased 12.3% as reported and 10.2% organic.

  • U.S. grew mid-single digits, returning to growth on the continued launch of the MiniMed™ 780G system; High-forties growth in U.S. insulin pump sales with continued sequential increases in customer base

  • Non-U.S. Developed Markets grew low-double digits on continued MiniMed™ 780G system adoption and increased CGM attachment rates

  • Received CE Mark for MiniMed™ 780G System with Simplera Sync™ CGM; limited European release expected in spring 2024 with phased European commercial launch in summer 2024

Patient Monitoring and Respiratory Interventions (PMRI) Update
Medtronic has decided to exit its ventilator product line and retain and combine the remaining PMRI businesses into one business unit called Acute Care and Monitoring (ACM). Exiting the increasingly unprofitable ventilator product line and combining the remaining businesses allows for increased investment in ACM with a focus on profitable growth. Given this increased investment along with an improved competitive landscape, the company has strong conviction in driving durable category leadership in this newly combined business. Medtronic will continue to honor existing ventilator contracts to serve the needs of its customers and their patients, and expects that existing manufacturers, who today account for the majority of the market, can meet customer demand for new ventilators moving forward.

Guidance
The company today raised its FY24 revenue growth and EPS guidance.

The company increased its FY24 organic revenue growth guidance from the prior 4.75% to the new range of 4.75% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue related to business separations reported as Other. Including Other revenue and the impact of foreign currency, if recent foreign currency exchange rates hold, FY24 revenue growth on a reported basis would be in the range of 2.9% to 3.3%.

The company increased its FY24 diluted non-GAAP EPS guidance from the prior range of $5.13 to $5.19 to the new range of $5.19 to $5.21 , a 4 cent increase at the midpoint that is reflective of the company's third quarter outperformance.

"In addition to delivering durable sales growth, we also drove improvements to our margins, as our cost efficiency programs helped to offset the impact of inflation, tax, and currency, contributing to our EPS and cash flow performance in the quarter," said Karen Parkhill , Medtronic EVP & chief financial officer. "Based on our year-to-date performance, including another solid financial performance this quarter, we are raising our full-year guidance on both the top and bottom lines. We remain focused on restoring our earnings power and creating value for our shareholders."

Video Webcast Information
Medtronic will host a video webcast today, February 20 , at 8:00 a.m. EST ( 7:00 a.m. CST ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com , and this earnings release will be archived at news.medtronic.com . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com .

Medtronic plans to report its FY24 fourth quarter results on Thursday, May 23, 2024 . For fiscal year 2025, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 20, 2024 , November 19, 2024 , February 18, 2025 , and Thursday, May 22, 2025 , respectively. Confirmation and additional details will be provided closer to the specific event.

Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the third quarter earnings presentation, click here .

MEDTRONIC PLC

WORLD WIDE REVENUE (1)

(Unaudited)



THIRD QUARTER



YEAR-TO-DATE


REPORTED




ORGANIC



REPORTED




ORGANIC

(in millions)

FY24


FY23


Growth


Currency
Impact (2)


Adjusted
FY24


Adjusted
FY23


Growth



FY24


FY23


Growth


Currency
Impact (2)


Adjusted
FY24


Adjusted
FY23


Growth

Cardiovascular

$    2,929


$    2,760


6.1 %


$        28


$    2,901


$    2,760


5.1 %



$    8,702


$    8,219


5.9 %


$        40


$    8,662


$    8,219


5.4 %

Cardiac Rhythm & Heart Failure

1,470


1,419


3.6


16


1,454


1,419


2.5



4,408


4,217


4.5


27


4,381


4,217


3.9

Structural Heart & Aortic

843


760


10.9


10


833


760


9.6



2,475


2,259


9.6


17


2,458


2,259


8.8

Coronary & Peripheral Vascular

616


581


6.0


2


614


581


5.7



1,818


1,744


4.2


(3)


1,821


1,744


4.4

Neuroscience

2,355


2,248


4.8


10


2,345


2,248


4.3



6,861


6,549


4.8


5


6,856


6,549


4.7

Cranial & Spinal Technologies

1,204


1,128


6.7


3


1,201


1,128


6.5



3,465


3,253


6.5



3,465


3,253


6.5

Specialty Therapies

726


699


3.9


3


723


699


3.4



2,126


2,052


3.6


(3)


2,129


2,052


3.8

Neuromodulation

425


420


1.2


4


421


420


0.2



1,270


1,244


2.1


9


1,261


1,244


1.4

Medical Surgical

2,148


2,068


3.9


20


2,128


2,068


2.9



6,329


6,003


5.4


36


6,293


6,003


4.8

Surgical & Endoscopy

1,616


1,546


4.5


18


1,598


1,546


3.4



4,803


4,514


6.4


35


4,768


4,514


5.6

Patient Monitoring & Respiratory Interventions

532


522


1.9


2


530


522


1.5



1,526


1,489


2.5


1


1,525


1,489


2.4

Diabetes

640


570


12.3


12


628


570


10.2



1,829


1,667


9.7


32


1,797


1,667


7.8

Other (3)

17


81


(79.0)


(2)






54


243


(77.8)


(7)




TOTAL

$    8,089


$    7,727


4.7 %


$        68


$    8,001


$    7,646


4.6 %



$  23,775


$  22,682


4.8 %


$      106


$  23,607


$  22,439


5.2 %



(1)

The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.

(2)

The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

(3)

Includes inorganic revenue from the divested Renal Care Solutions business and Transition Manufacturing Agreements from previously divested businesses.

MEDTRONIC PLC

U.S. (1)(2) REVENUE

(Unaudited)



THIRD QUARTER



YEAR-TO-DATE


REPORTED


ORGANIC



REPORTED


ORGANIC

(in millions)

FY24


FY23


Growth


Adjusted
FY24


Adjusted
FY23


Growth



FY24


FY23


Growth


Adjusted
FY24


Adjusted
FY23


Growth

Cardiovascular

$    1,373


$    1,363


0.7 %


$    1,373


$    1,363


0.7 %



$    4,149


$    4,059


2.2 %


$    4,149


$    4,059


2.2 %

Cardiac Rhythm & Heart Failure

745


753


(1.1)


745


753


(1.1)



2,247


2,233


0.6


2,247


2,233


0.6

Structural Heart & Aortic

363


337


7.7


363


337


7.7



1,087


997


9.0


1,087


997


9.0

Coronary & Peripheral Vascular

265


274


(3.3)


265


274


(3.3)



816


829


(1.6)


816


829


(1.6)

Neuroscience

1,556


1,507


3.3


1,556


1,507


3.3



4,614


4,437


4.0


4,614


4,437


4.0

Cranial & Spinal Technologies

875


824


6.2


875


824


6.2



2,560


2,404


6.5


2,560


2,404


6.5

Specialty Therapies

407


402


1.2


407


402


1.2



1,202


1,186


1.3


1,202


1,186


1.3

Neuromodulation

275


281


(2.1)


275


281


(2.1)



852


848


0.5


852


848


0.5

Medical Surgical

960


959


0.1


960


959


0.1



2,805


2,685


4.5


2,805


2,685


4.5

Surgical & Endoscopy

663


674


(1.6)


663


674


(1.6)



1,971


1,888


4.4


1,971


1,888


4.4

Patient Monitoring & Respiratory Interventions

297


285


4.2


297


285


4.2



834


797


4.6


834


797


4.6

Diabetes

224


215


4.2


224


215


4.2



629


650


(3.2)


629


650


(3.2)

Other (3)

7


17


(58.8)






23


66


(65.2)




TOTAL

$    4,120


$    4,062


1.4 %


$    4,113


$    4,045


1.7 %



$   12,219


$   11,897


2.7 %


$   12,197


$   11,831


3.1 %



(1)

U.S. includes the United States and U.S. territories.

(2)

The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.

(3)

Includes inorganic revenue from the divested Renal Care Solutions business and Transition Manufacturing Agreements from previously divested businesses.

MEDTRONIC PLC

WORLD WIDE REVENUE: GEOGRAPHIC (1)(2)

(Unaudited)



THIRD QUARTER



YEAR-TO-DATE


REPORTED




ORGANIC



REPORTED




ORGANIC

(in millions)

FY24


FY23


Growth


Currency
Impact (3)


Adjusted
FY24


Adjusted
FY23


Growth



FY24


FY23


Growth


Currency
Impact (3)


Adjusted
FY24


Adjusted
FY23


Growth

U.S.

$    1,373


$    1,363


0.7 %


$         —


$    1,373


$    1,363


0.7 %



$    4,149


$    4,059


2.2 %


$         —


$    4,149


$     4,059


2.2 %

Non-U.S. Developed

950


859


10.6


30


920


859


7.1



2,818


2,553


10.4


75


2,743


2,553


7.4

Emerging Markets

607


538


12.8


(2)


609


538


13.2



1,734


1,607


7.9


(34)


1,768


1,607


10.0

Cardiovascular

2,929


2,760


6.1


28


2,901


2,760


5.1



8,702


8,219


5.9


40


8,662


8,219


5.4

U.S.

1,556


1,507


3.3



1,556


1,507


3.3



4,614


4,437


4.0



4,614


4,437


4.0

Non-U.S. Developed

442


401


10.2


10


432


401


7.7



1,257


1,189


5.7


20


1,237


1,189


4.0

Emerging Markets

357


341


4.7



357


341


4.7



991


923


7.4


(15)


1,006


923


9.0

Neuroscience

2,355


2,248


4.8


10


2,345


2,248


4.3



6,861


6,549


4.8


5


6,856


6,549


4.7

U.S.

960


959


0.1



960


959


0.1



2,805


2,685


4.5



2,805


2,685


4.5

Non-U.S. Developed

758


725


4.6


15


743


725


2.5



2,270


2,144


5.9


36


2,234


2,144


4.2

Emerging Markets

429


384


11.7


5


424


384


10.4



1,254


1,174


6.8



1,254


1,174


6.8

Medical Surgical

2,148


2,068


3.9


20


2,128


2,068


2.9



6,329


6,003


5.4


36


6,293


6,003


4.8

U.S.

224


215


4.2



224


215


4.2



629


650


(3.2)



629


650


(3.2)

Non-U.S. Developed

322


274


17.5


13


309


274


12.8



947


792


19.6


36


911


792


15.0

Emerging Markets

94


80


17.5


(1)


95


80


18.8



253


226


11.9


(4)


257


226


13.7

Diabetes

640


570


12.3


12


628


570


10.2



1,829


1,667


9.7


32


1,797


1,667


7.8

U.S.

7


17


(58.8)







23


66


(65.2)





Non-U.S. Developed

2


36


(94.4)


(1)






14


101


(86.1)


(4)




Emerging Markets

8


28


(71.4)


(1)






18


76


(76.3)


(3)




Other (4)

17


81


(79.0)


(2)






54


243


(77.8)


(7)




U.S.

4,120


4,062


1.4



4,113


4,045


1.7



12,219


11,897


2.7



12,197


11,831


3.1

Non-U.S. Developed

2,473


2,294


7.8


67


2,403


2,258


6.4



7,305


6,779


7.8


162


7,125


6,678


6.7

Emerging Markets

1,495


1,371


9.0


2


1,484


1,343


10.5



4,251


4,006


6.1


(56)


4,285


3,929


9.1

TOTAL

$    8,089


$    7,727


4.7 %


$         68


$    8,001


$    7,646


4.6 %



$   23,775


$   22,682


4.8 %


$       106


$   23,607


$   22,439


5.2 %



(1)

U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.

(2)

The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.

(3)

The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

(4)

Includes inorganic revenue from the divested Renal Care Solutions business and Transition Manufacturing Agreements from previously divested businesses.

MEDTRONIC PLC

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)



Three months ended


Nine months ended

(in millions, except per share data)

January 26,
2024


January 27,
2023


January 26,
2024


January 27,
2023

Net sales

$            8,089


$            7,727


$          23,775


$          22,682

Costs and expenses:








Cost of products sold, excluding amortization of intangible assets

2,782


2,689


8,172


7,740

Research and development expense

695


688


2,060


2,055

Selling, general, and administrative expense

2,673


2,615


7,971


7,799

Amortization of intangible assets

419


431


1,274


1,275

Restructuring charges, net

20


38


114


81

Certain litigation charges



105


Other operating expense (income), net

17


(125)


(13)


(187)

Operating profit

1,483


1,392


4,091


3,920

Other non-operating income, net

(177)


(149)


(407)


(342)

Interest expense, net

188


167


517


449

Income before income taxes

1,472


1,375


3,982


3,813

Income tax provision

135


146


936


1,218

Net income

1,337


1,229


3,045


2,595

Net income attributable to noncontrolling interests

(15)


(6)


(23)


(17)

Net income attributable to Medtronic

$            1,322


$            1,222


$            3,022


$            2,579

Basic earnings per share

$               0.99


$               0.92


$               2.27


$               1.94

Diluted earnings per share

$               0.99


$               0.92


$               2.27


$               1.94

Basic weighted average shares outstanding

1,329.7


1,330.2


1,330.1


1,329.6

Diluted weighted average shares outstanding

1,331.7


1,332.0


1,332.4


1,332.8


The data in the schedule above has been intentionally rounded to the nearest million, and therefore, the quarterly amounts may not sum to the fiscal year-to-date amounts.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS (1)

(Unaudited)



Three months ended January 26, 2024

(in millions, except per share data)

Net Sales


Cost of
Products
Sold


Gross
Margin
Percent


Operating
Profit


Operating
Profit
Percent


Income
Before
Income
Taxes


Net Income
attributable
to
Medtronic


Diluted
EPS


Effective
Tax Rate

GAAP

$  8,089


$   2,782


65.6 %


$     1,483


18.3 %


$    1,472


$       1,322


$     0.99


9.2 %

Non-GAAP Adjustments:


















Amortization of intangible assets




419


5.2


419


354


0.27


15.5

Restructuring and associated costs (2)


(12)


0.1


55


0.7


55


46


0.03


16.4

Acquisition and divestiture-related items (3)


(12)


0.1


58


0.7


58


52


0.04


10.3

(Gain)/loss on minority investments (4)






24


24


0.02


Medical device regulations (5)


(18)


0.2


26


0.3


26


21


0.02


19.2

Certain tax adjustments, net (6)







(92)


(0.07)


Non-GAAP

$  8,089


$   2,740


66.1 %


$     2,042


25.2 %


$    2,055


$       1,728


$     1.30


15.2 %

Currency impact

(68)


(66)


0.6


164


2.3






0.11



Currency Adjusted

$  8,021


$   2,674


66.7 %


$     2,206


27.5 %






$     1.41






















Three months ended January 27, 2023

(in millions, except per share data)

Net Sales


Cost of
Products
Sold


Gross
Margin
Percent


Operating
Profit


Operating
Profit
Percent


Income
Before
Income
Taxes


Net Income
attributable
to
Medtronic


Diluted
EPS


Effective
Tax Rate

GAAP

$  7,727


$   2,689


65.2 %


$     1,392


18.0 %


$    1,375


$       1,222


$     0.92


10.6 %

Non-GAAP Adjustments:


















Amortization of intangible assets




431


5.6


431


367


0.28


15.1

Restructuring and associated costs (2)


(26)


0.3


104


1.3


104


83


0.06


20.2

Acquisition and divestiture-related items (3)


(9)


0.1


34


0.4


34


29


0.03


26.7

(Gain)/loss on minority investments (4)






(8)


(8)


(0.01)


Medical device regulations (5)


(23)


0.3


37


0.5


37


31


0.02


18.9

Certain tax adjustments, net







3



Non-GAAP

$  7,727


$   2,630


66.0 %


$     1,998


25.9 %


$    1,973


$       1,727


$     1.30


12.1 %


See description of non-GAAP financial measures contained in the press release dated February 20, 2024.

(1)

The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.

(2)

Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.

(3)

The charges primarily include business combination costs, changes in fair value of contingent consideration, and charges related to the potential separation of the Patient Monitoring and Respiratory Interventions businesses within our Medical Surgical Portfolio.

(4)

We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

(5)

The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.

(6)

The net tax benefit primarily relates to a change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS (1)

(Unaudited)



Nine months ended January 26, 2024

(in millions, except per share data)

Net Sales


Cost of
Products
Sold


Gross
Margin
Percent


Operating
Profit


Operating
Profit
Percent


Income
Before
Income
Taxes


Net Income
attributable
to
Medtronic


Diluted
EPS


Effective
Tax Rate

GAAP

$  23,775


$   8,172


65.6 %


$     4,091


17.2 %


$    3,982


$         3,022


$     2.27


23.5 %

Non-GAAP Adjustments:


















Amortization of intangible assets




1,274


5.4


1,274


1,078


0.81


15.4

Restructuring and associated costs (2)


(43)


0.2


237


1.0


237


198


0.15


16.5

Acquisition and divestiture-related items (3)


(24)


0.1


165


0.7


165


149


0.11


9.7

Certain litigation charges




105


0.4


105


81


0.06


22.9

(Gain)/loss on minority investments (4)






113


109


0.08


4.4

Medical device regulations (5)


(60)


0.3


88


0.4


88


70


0.05


20.5

Certain tax adjustments, net (6)







282


0.21


Non-GAAP

$  23,775


$   8,046


66.2 %


$     5,961


25.1 %


$    5,965


$         4,988


$     3.74


16.0 %

Currency impact

(106)


(132)


0.4


406


1.8






0.27



Currency Adjusted

$  23,669


$   7,914


66.6 %


$     6,367


26.9 %






$     4.01






















Nine months ended January 27, 2023

(in millions, except per share data)

Net Sales


Cost of
Products
Sold


Gross
Margin
Percent


Operating
Profit


Operating
Profit
Percent


Income
Before
Income
Taxes


Net Income
attributable
to
Medtronic


Diluted
EPS


Effective
Tax Rate

GAAP

$  22,682


$   7,740


65.9 %


$     3,920


17.3 %


$    3,813


$         2,579


$     1.94


31.9 %

Non-GAAP Adjustments:


















Amortization of intangible assets




1,275


5.6


1,275


1,082


0.81


15.2

Restructuring and associated costs (2)


(67)


0.3


275


1.2


275


219


0.16


20.0

Acquisition and divestiture-related items (3)


(59)


0.3


207


0.9


207


186


0.14


32.3

(Gain)/loss on minority investments (4)






(23)


(23)


(0.02)


Medical device regulations (5)


(62)


0.3


107


0.5


107


87


0.07


18.7

Debt redemption premium and other charges (7)






53


42


0.03


20.8

Certain tax adjustments, net (8)







783


0.59


Non-GAAP

$  22,682


$   7,551


66.7 %


$     5,783


25.5 %


$    5,706


$         4,953


$     3.72


12.9 %


See description of non-GAAP financial measures contained in the press release dated February 20, 2024.

(1)

The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.

(2)

Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.

(3)

The charges primarily include business combination costs, changes in fair value of contingent consideration, and charges related to the potential separation of the Patient Monitoring and Respiratory Interventions businesses within our Medical Surgical Portfolio.

(4)

We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

(5)

The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific period.

(6)

The net charge primarily relates to an income tax reserve adjustment associated with the June 1, 2023, Israeli Central-Lod District Court decision and the establishment of a valuation allowance against certain net operating losses which were partially offset by a benefit from the change in a Swiss Cantonal tax rate associated with previously established deferred tax assets from intercompany intellectual property transactions and the step up in tax basis for Swiss Cantonal purposes.

(7)

The charges relate to the early redemption of approximately $2.3 billion of debt and were recorded within interest expense, net within the consolidated statements of income.

(8)

The charge primarily relates to a $764 million reserve adjustment that was a direct result of the U.S. Tax Court opinion, issued on August 18, 2022, on the previously disclosed litigation regarding the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS (1)

(Unaudited)



Three months ended January 26, 2024

(in millions)

Net Sales


SG&A
Expense


SG&A
Expense as
a % of Net
Sales


R&D
Expense


R&D
Expense
as a % of
Net Sales


Other
Operating
(Income)
Expense,
net


Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales


Other Non-
Operating
Income, net

GAAP

$      8,089


$     2,673


33.0 %


$       695


8.6 %


$           17


0.2 %


$          (177)

Non-GAAP Adjustments:
















Restructuring and associated costs (2)


(23)


(0.3)






Acquisition and divestiture-related items (3)


(24)


(0.3)




(23)


(0.3)


Medical device regulations (4)




(8)


(0.1)




(Gain)/loss on minority investments (5)








(24)

Non-GAAP

$      8,089


$     2,625


32.5 %


$       687


8.5 %


$           (6)


(0.1) %


$          (201)

Currency impact

(68)


(25)


(0.1)



0.1


(142)


(1.7)


2

Currency Adjusted

$      8,021


$     2,600


32.4 %


$       687


8.6 %


$       (148)


(1.8) %


$          (199)


Nine months ended January 26, 2024

(in millions)

Net Sales


SG&A
Expense


SG&A
Expense as
a % of Net
Sales


R&D
Expense


R&D
Expense
as a % of
Net Sales


Other
Operating
(Income)
Expense,
net


Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales


Other Non-
Operating
Income, net

GAAP

$    23,775


$     7,971


33.5 %


$    2,060


8.7 %


$         (13)


(0.1) %


$          (407)

Non-GAAP Adjustments:
















Restructuring and associated costs (2)


(80)


(0.3)






Acquisition and divestiture-related items (3)


(66)


(0.3)




(76)


(0.3)


Medical device regulations (4)


(1)



(27)


(0.1)




(Gain)/loss on minority investments (5)








(113)

Non-GAAP

$    23,775


$     7,824


32.9 %


$    2,033


8.6 %


$         (89)


(0.4) %


$          (520)

Currency impact

(106)


(56)


(0.1)


2



(327)


(1.4)


8

Currency Adjusted

$    23,669


$     7,768


32.8 %


$    2,035


8.6 %


$       (416)


(1.8) %


$          (512)


See description of non-GAAP financial measures contained in the press release dated February 20, 2024.

(1)

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

(2)

Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program, consulting expenses, and asset write-offs.

(3)

The charges primarily include business combination costs, changes in fair value of contingent consideration, and charges related to the potential separation of the Patient Monitoring and Respiratory Interventions businesses within our Medical Surgical Portfolio.

(4)

The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period.

(5)

We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS (1)

(Unaudited)



Nine months ended

(in millions)

January 26, 2024


January 27, 2023

Net cash provided by operating activities

$                      4,010


$                      3,579

Additions to property, plant, and equipment

(1,161)


(1,081)

Free Cash Flow (2)

$                      2,849


$                      2,498


See description of non-GAAP financial measures contained in the press release dated February 20, 2024.

(1)

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

(2)

Free cash flow represents operating cash flows less property, plant, and equipment additions.

MEDTRONIC PLC

CONSOLIDATED BALANCE SHEETS

(Unaudited)


(in millions)


January 26, 2024


April 28, 2023

ASSETS





Current assets:





Cash and cash equivalents


$               1,623


$               1,543

Investments


6,698


6,416

Accounts receivable, less allowances and credit losses of $180 and $176, respectively


5,968


5,998

Inventories, net


5,726


5,293

Other current assets


2,499


2,425

Total current assets


22,513


21,675

Property, plant, and equipment, net


5,838


5,569

Goodwill


41,160


41,425

Other intangible assets, net


13,690


14,844

Tax assets


3,599


3,477

Other assets


4,036


3,959

Total assets


$             90,836


$             90,948

LIABILITIES AND EQUITY





Current liabilities:





Current debt obligations


$               1,029


$                     20

Accounts payable


1,992


2,662

Accrued compensation


2,174


1,949

Accrued income taxes


1,109


840

Other accrued expenses


3,488


3,581

Total current liabilities


9,793


9,051

Long-term debt


24,153


24,344

Accrued compensation and retirement benefits


1,049


1,093

Accrued income taxes


1,821


2,360

Deferred tax liabilities


615


708

Other liabilities


1,410


1,727

Total liabilities


38,840


39,283

Commitments and contingencies





Shareholders' equity:





Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,329,653,024 and
1,330,809,036 shares issued and outstanding, respectively



Additional paid-in capital


24,589


24,590

Retained earnings


30,661


30,392

Accumulated other comprehensive loss


(3,459)


(3,499)

Total shareholders' equity


51,792


51,483

Noncontrolling interests


204


182

Total equity


51,996


51,665

Total liabilities and equity


$             90,836


$             90,948


The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

MEDTRONIC PLC

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)



Nine months ended

(in millions)

January 26, 2024


January 27, 2023

Operating Activities:




Net income

$                3,045


$                2,595

Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

1,993


2,018

Provision for credit losses

62


54

Deferred income taxes

(250)


(78)

Stock-based compensation

303


280

Loss on debt extinguishment


53

Other, net

265


182

Change in operating assets and liabilities, net of acquisitions and divestitures:




Accounts receivable, net

(140)


(408)

Inventories, net

(530)


(936)

Accounts payable and accrued liabilities

(253)


163

Other operating assets and liabilities

(485)


(344)

Net cash provided by operating activities

4,010


3,579

Investing Activities:




Acquisitions, net of cash acquired

(74)


(1,867)

Additions to property, plant, and equipment

(1,161)


(1,081)

Purchases of investments

(5,422)


(5,472)

Sales and maturities of investments

5,142


5,387

Other investing activities, net

(155)


15

Net cash used in investing activities

(1,670)


(3,018)

Financing Activities:




Change in current debt obligations, net

1,010


625

Proceeds from short-term borrowings (maturities greater than 90 days)


2,284

Issuance of long-term debt


3,430

Payments on long-term debt


(3,083)

Dividends to shareholders

(2,753)


(2,711)

Issuance of ordinary shares

206


209

Repurchase of ordinary shares

(510)


(548)

Other financing activities

(44)


(276)

Net cash used in financing activities

(2,091)


(70)

Effect of exchange rate changes on cash and cash equivalents

(170)


317

Net change in cash and cash equivalents

80


808

Cash and cash equivalents at beginning of period

1,543


3,714

Cash and cash equivalents at end of period

$                1,623


$                4,521





Supplemental Cash Flow Information




Cash paid for:




Income taxes

$                1,403


$                1,314

Interest

568


262


The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow on X and LinkedIn .

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

NON-GAAP FINANCIAL MEASURES
This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2023.

Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

Contacts:




Erika Winkels

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-8478

+1-763-505-4626

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-third-quarter-fiscal-2024-financial-results-302065574.html

SOURCE Medtronic plc

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2024/20/c3293.html

News Provided by Canada Newswire via QuoteMedia

MDT
The Conversation (0)

PrairieSky Announces Fourth Quarter And Year-End Results For 2023, Including Record Oil Royalty Production, Strong Leasing Activity And Increased Annual Dividend

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its fourth quarter (" Q4 2023 ") and year-end operating and financial results for the period ended December 31, 2023. PrairieSky is also pleased to announce a 4% increase in its annual dividend to $1.00 per common share ($0.25 per common share quarterly).

Fourth Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces 2023 Third Quarter Results

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its third quarter (" Q3 2023 ") results for the three-month period ended September 30, 2023.

Third Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
doctor with hands together, palms up below digital medical symbols

Innovations and Opportunities in European Healthcare Technologies

In recent years, European companies have emerged as trailblazers in healthcare technology, effectively changing the face of health and patient care. Through innovation, they're not only improving systems, processes and patient outcomes but also saving lives.

These advanced European technologies are often only distributed and implemented exclusively within the European Union. The good news is that it doesn't need to stay this way.

Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.

Keep reading...Show less

PrairieSky Announces 2023 Second Quarter Results, Including Record Oil Royalty Production

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its second quarter (" Q2 2023 ") results for the three-month period ended June 30, 2023.

Second Quarter Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×